G551D and G1349D, Two CF-associated Mutations in the Signature Sequences of CFTR, Exhibit Distinct Gating Defects by Bompadre, Silvia G. et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
G
e
n
e
r
a
l
 
P
h
y
s
i
o
l
o
g
y
J. Gen. Physiol. © The Rockefeller University Press  $15.00
Volume 129  Number 4  April 2007  285–298
http://www.jgp.org/cgi/doi/10.1085/jgp.200609667
285
ARTICLE
G551D and G1349D, Two CF-associated Mutations in the Signature 
Sequences of CFTR, Exhibit Distinct Gating Defects
Silvia G. Bompadre,1,2 Yoshiro Sohma,2,3 Min Li,1,2 and Tzyh-Chang Hwang1,2
1 Department of Medical Pharmacology and Physiology, 2Dalton Cardiovascular Research Center, University of Missouri-Columbia, 
Columbia, MO 65211
3Department of Physiology, Osaka Medical College, Takatsuki, Osaka 569-8686, Japan
Mutations in the gene encoding cystic fi  brosis transmembrane conductance regulator (CFTR) result in cystic fi  bro-
sis (CF). CFTR is a chloride channel that is regulated by phosphorylation and gated by ATP binding and hydrolysis 
at its nucleotide binding domains (NBDs). G551D-CFTR, the third most common CF-associated mutation, has 
been characterized as having a lower open probability (Po) than wild-type (WT) channels. Patients carrying the 
G551D mutation present a severe clinical phenotype. On the other hand, G1349D, also a mutant with gating dys-
function, is associated with a milder clinical phenotype. Residues G551 and G1349 are located at equivalent posi-
tions in the highly conserved signature sequence of each NBD. The physiological importance of these residues lies 
in the fact that the signature sequence of one NBD and the Walker A and B motifs from the other NBD form the 
ATP-binding pocket (ABP1 and ABP2, named after the location of the Walker A motif) once the two NBDs dimerize. 
Our studies show distinct gating characteristics for these mutants. The G551D mutation completely eliminates 
the ability of ATP to increase the channel activity, and the observed activity is  100-fold smaller than WT-CFTR. 
G551D-CFTR does not respond to ADP, AMP-PNP, or changes in [Mg2+]. The low activity of G551D-CFTR likely 
represents the rare ATP-independent gating events seen with WT channels long after the removal of ATP. G1349D-
CFTR maintains ATP dependence, albeit with a Po  10-fold lower than WT. Interestingly, compared to WT results, 
the ATP dose–response relationship of G1349D-CFTR is less steep and shows a higher apparent affi  nity for ATP. 
G1349D data could be well described by a gating model that predicts that binding of ATP at ABP1 hinders channel 
opening. Thus, our data provide a quantitative explanation at the single-channel level for different phenotypes 
presented by patients carrying these two mutations. In addition, these results support the idea that CFTR’s two 
ABPs play distinct functional roles in gating.
INTRODUCTION
CFTR, a member of the ATP-binding cassette (ABC) 
transporter family, is a chloride channel that is gated by 
ATP binding and hydrolysis. By analogy to other ABC 
transporters, it is proposed that an ATP-driven dimer-
ization of CFTR’s two nucleotide binding domains 
(NBD1 and NBD2) leads to the opening of the channel, 
and hydrolysis at NBD2 leads to dimer dissociation and, 
consequently, closing of the channel (for reviews see 
Gadsby et al., 2006; Zhou and Hwang, 2007). Once the 
two NBDs dimerize, each ATP-binding pocket (ABP) is 
composed of the Walker A and B motifs of one NBD 
and the signature sequence of the partner NBD (Fig. 1). 
We therefore defi  ne, here, ABP1 as the binding site that 
consists of the Walker A and B motifs from the N-terminal 
NBD (i.e., NBD1) and the signature sequence from the 
C-terminal NBD (i.e., NBD2). An equivalent defi  nition 
is made for ABP2.
Mutations in the CFTR gene cause the genetic disease 
cystic fi  brosis (Riordan et al., 1989), the most common 
lethal autosomal recessive disorder in Caucasian popu-
lations (Riordan et al., 1989; Welsh and Smith, 1993; 
Tsui and Durie, 1997). CF is manifested by a defective 
chloride transport across the epithelial cells in various 
tissues such as respiratory, gastrointestinal, hepatobili-
ary, and reproductive tracts (Quinton, 1990). More 
than 1,400 mutations have been identifi  ed as disease 
  associated in the cystic fi  brosis mutation database (www
.genet.sickkids.on.ca/). These mutations can be divided 
into four classes based on the mechanisms that disrupt 
CFTR function (Welsh and Smith, 1993): defective pro-
tein production (I); defective protein processing (II); 
defective activation and regulation (III), including G551D 
and G1349D; and defective conductance (IV).
G551D is the third overall most common CF muta-
tion with a worldwide frequency of  3% (www.genet
.sickkids.on.ca/cftr). This mutation is associated with a 
severe phenotype characterized by pulmonary dysfunc-
tion and pancreatic insuffi  ciency (Cutting et al., 1990; 
Kerem et al., 1990). The result of this glycine-to-aspartate 
mutation at position 551 is a significantly decreased 
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chloride current due to a drastic reduction of the chan-
nel activity (Drumm et al., 1991). The importance of 
the G551 residue also lies in the fact that it is located in 
the signature sequence of CFTR’s NBD1 (Fig. 1). Inter-
estingly, the corresponding residue, G1349, in the sig-
nature sequence of NBD2, has also been identifi  ed as 
disease associated when it is mutated to aspartate (Beaudet 
et al., 1991). However, the G1349D mutation is associ-
ated with a milder clinical phenotype (Brancolini et al., 
1995, Salvatore et al., 2002).
Although G551D-CFTR and G1349D-CFTR have been 
used in pharmacological studies for years (e.g., Illek 
et al., 1999; Galietta et al., 2001; Moran et al., 2005; 
Pedemonte et al., 2005), little is known about the mecha-
nism responsible for their dysfunction due to limited 
functional studies of these two mutants at a single-
  channel level (e.g., Cai et al., 2006). It is also puzzling why 
analogous mutations at two equivalent positions would 
cause different phenotypes if the two ABPs were equally 
important in opening CFTR channels as proposed pre-
viously (Vergani et al., 2003; c.f. Zhou et al., 2006). 
Gregory et al. (1991) reported that these two mutant 
proteins have normal biosynthesis, traffi  cking, and pro-
cessing. Using a fl  uorescence-based assay they observed 
that G551D-CFTR channels lack functional activity, even 
though the channels can be normally phosphorylated 
in the R domain (Chang et al., 1993). Logan et al. 
(1994) reported that as a consequence of the G551D, or 
G1349D mutation, nucleotide binding to isolated re-
combinant NBD1 and NBD2 is decreased. The signifi  -
cance of this early biochemical study is unclear in light 
of the latest fi  nding that CFTR’s two NBDs likely dimer-
ize with ATP molecules sandwiched at the dimer inter-
face as seen in other ABC transporters (Vergani et al., 
2005). Wilkinson et al. (1996) measured the rates of 
activation and deactivation of macroscopic CFTR cur-
rents in Xenopus oocytes and found that the apparent 
on rate of channel activation by cAMP for G551D-
CFTR or G1349D-CFTR was drastically reduced. A pos-
sible explanation for this reduction is an increase of the 
closed time of the channel, as demonstrated by Cai 
et al. (2006). However, the low Po of these two mu-
tants makes it very diffi  cult to accurately quantify single 
channel kinetics.
We have studied the response of G551D-CFTR and 
G1349D-CFTR to ATP, ADP, and AMP-PNP in excised 
inside-out membrane patches. Although both mutants 
show lower Po than WT-CFTR, as shown previously 
(Li et al., 1996; Cai et al., 2006), they exhibit very different 
behaviors. The G551D mutation completely abolishes the 
response of the channel to ATP and ADP, whereas 
the G1349D mutation remains responsive to ATP and 
the ATP-induced activity can be inhibited by ADP. 
These results are consistent with the idea that ATP bind-
ing to the ABP2 site (formed by the signature sequence 
of NBD1 and the Walker A and B motifs of NBD2) is 
critical to catalyze ATP-dependent channel opening 
(Vergani et al., 2003; Berger et al., 2005; Bompadre 
et al., 2005b; Zhou et al., 2006). Interestingly, compared 
with WT data, the ATP dose–response relationship for 
G1349D-CFTR is less steep and shows an increase of 
the apparent affi  nity for ATP. These features of the 
ATP dose response for G1349D-CFTR could be repro-
duced by assuming that ATP binding to ABP1, where 
the mutation is located, hinders channel opening. The 
fundamental mechanism responsible for the different 
behavior of these two mutant channels and the poten-
tial clinical implications of our results will be discussed.
MATERIALS AND METHODS
Site-directed Mutagenesis
The construction of the expression vector pcDNA 3.1 Zeo(+) 
(Invitrogen) containing WT CFTR cDNA has been described pre-
viously (Powe et al., 2002). Point mutations (G551D and G1349D) 
were introduced into WT-CFTR by QuikChange XL method 
(Stratagene). The entire CFTR cDNA was sequenced (DNA core, 
University of Missouri-Columbia) to confi  rm the mutation. This 
strategy has been routinely used in our laboratory to obtain 
  mutant CFTR constructs.
Cell Culture and Transient Expression
CHO cells were grown at 37°C and 5% CO2 in Dulbecco’s modi-
fi  ed Eagle’s medium supplemented with 10% FBS. To transiently 
express CFTR, CHO cells were grown in 35-mm tissue culture 
dishes 1 d before transfection. The DNA construct, encoding WT 
or mutant CFTR, was cotransfected with pEGFP-C3 (CLONTECH 
Laboratories Inc.) encoding GFP using SuperFect transfection 
Figure 1.  Cartoon depicting the location of G551 and G1349 in 
CFTR’s two ATP-binding pockets. The G551 residue is located in 
the signature sequence of NBD1 while the G1349 is located in the 
signature sequence of NBD2. CFTR has two ATP-binding pockets 
(ABPs) composed by the Walker A and B motifs of one NBD and 
the signature sequence of the partner NBD. The ATP-binding 
pockets are named after the position of the Walker A motif (i.e., 
ABP1 is composed of the Walker A and B motifs of NBD1 and the 
signature sequence of NBD2). Thus the G551D mutation is 
  located in ABP2 and the G1349D mutation is located in ABP1.  Bompadre et al. 287
  reagent (QIAGEN) according to the manufacturer’s protocols. 
The transfected cells were used for electrophysiological studies 
2–6 d after transfection.
Western Blot Analysis
48 h after transfection, cells from confl  uent 35-mm dishes were 
washed with PBS and lysed in 1× Laemmli sample buffer (Bio-
Rad Laboratories Inc.). DNA was sheared by brief sonication. 
Whole cell lysates were separated on 7.5% Tris-HCl SDS-PAGE 
gels (Bio-Rad Laboratories Inc.) and transferred onto a nitro-
cellulose membrane. The membrane was blocked with 5% milk in 
TBST buffer (20 mM Tris, 137 mM NaCl, 0.05% Tween) at room 
temperature for 1 h and then probed with primary antibody 
against CFTR (clone M3A7, Chemicon) in PBS at 4°C overnight. 
M3A7 is a mouse monoclonal antibody that recognizes an epitope 
at the C-terminal end, in the region of residues 1370 to 1380. The 
membrane was washed with TBST three times and then incubated 
with the horseradish peroxidase–conjugated secondary antibody 
(donkey anti-mouse IgG; Jackson ImmunoResearch Laboratories) 
for 2 h at room temperature. The membrane was developed with 
chemiluminescence reagent (Pierce Chemical Co.) for 5 min and 
exposed to fi  lm (Fuji Photo Film Co.). The blot was stripped and 
reprobed with an anti-vimentin antibody (C-20, Santa Cruz Bio-
technology Inc.) as an internal control of protein loading.
Electrophysiological Recordings and Data Analysis
All data were recorded at room temperature using an EPC9 
  amplifi  er (HEKA). For whole-cell recordings, the membrane 
potential was held at 0 mV. Current traces were fi  ltered at 1 kHz 
with a built-in four-pole Bessel fi  lter, and then digitized to the 
computer at a sampling rate of 2 kHz. Ramp voltages to −100 mV 
(in 400 ms) and to +100 mV (in 400 ms) were generated with 
Pulse software (HEKA). The net current was calculated as the 
current between 0 and +100 mV minus the basal current at 
the same voltages (leak current) using Igor software (Wavemet-
rics). The membrane capacitance was obtained from the EPC9 
amplifi  er after the compensation of the capacitance current. 
The mean current density was calculated as the ratio between 
the net mean current and the membrane capacitance. The bath 
solution contained (in mM) 145 NaCl, 5 KCl, 2 MgCl2, 1 CaCl2, 
5 glucose, and 5 HEPES (pH 7.4 with NaOH). 20 mM sucrose 
is added to the bath solution to prevent activation of swelling-
induced currents. The pipette solution contained (in mM) 
10 EGTA, 10 HEPES, 20 TEACl, 10 MgATP, 2 MgCl2, 101 CsCl, 
and 5.8 glucose.
For inside-out recordings, the membrane potential was held at 
−50 mV for all experiments. Data were fi  ltered at 100 Hz with an 
eight-pole Bessel fi  lter (Warner Instrument) and digitized at a 
sampling rate of 500 Hz. Downward defl  ections in the current 
trace indicate channel opening. The pipette solution contained 
(in mM) 140 NMDG-Cl, 2 MgCl2, 5 CaCl2, and HEPES (pH 7.4 
with NMDG). The standard perfusion solution for inside-out 
patches contained (in mM) 150 NMDG-Cl, 10 EGTA, 10 HEPES, 
8 TRIS, and 2 MgCl2 (pH 7.4 with NMDG). For experiments with 
magnesium-free solutions, we used a formula based on Dousmanis 
et al. (2002). EGTA in the perfusion solution was substituted with 
2 mM CDTA to buffer magnesium.
The steady-state mean current and single channel amplitudes 
were calculated with Igor. Open times were calculated using a 
program developed by Csanady (2000) from recordings with up 
to four channel open steps (for details see Bompadre et al., 
2005a). In brief, current traces were baseline corrected, idealized, 
and fi  tted to a three-state model C«O«B, where O and C are 
open and closed states, respectively. B is a blocked state induced 
by an intrinsic blocker (Zhou et al., 2001). To determine the true 
ATP-dependent parameters, the ATP-independent brief closures 
(fl  ickers) observed within a burst had to be removed. The rate 
constants rCO, rOC, rOB, and rBO are extracted by a simultaneous fi  t 
to the dwell-time histograms of all conductance levels. Mean burst 
durations were calculated as τb = (1/ rOC)(1 + rOB / rBO). Then, 
the burst time (τb) corresponds to the ATP-dependent open time 
of the channel. For kinetic modeling, we employed the Q-matrix 
method (Colquhoun and Hawkes, 1995) to calculate the steady-
state solution for the open probability for Schemes A and B 
(Figs. 10 and 11).
Statistics
Results are expressed as means ± SEM for n cells. To compare 
data, Student t tests were performed using SigmaPlot (SPSS Science, 
version 8.0.2); P < 0.01 was considered statistically signifi  cant.
Reagents
Mg-ATP and ADP were purchased from Sigma-Aldrich. PKA was 
purchased from Promega. AMP-PNP was purchased from Roche 
and stored as 250 mM stock in H2O at −20°C.
RESULTS
Expression of G551D-CFTR and G1349D-CFTR
It has been previously reported that neither G551D-
CFTR nor G1349D-CFTR exhibit traffi  cking defects in 
COS cells (Gregory et al., 1991). To ensure that abnormal 
traffi  cking was also absent when these mutants are expre-
ssed in CHO cells, we performed a Western blot analysis. 
Figure 2.  G551D-CFTR and G1349D-CFTR expression in CHO 
cells. (A) Western blot analysis for WT-, G551D-, and G1349D-
CFTR. Mature fully glycosylated CFTR and core-glycosylated CFTR 
are labeled as Band C and Band B, respectively. The same blot was 
probed with an antibody against the cytoskeletal protein vimentin 
as a control for protein loading. Similar results were obtained in 
three separate preparations. (B) Mean current densities obtained 
from whole-cell experiments for G551D (n = 30), G1349D (n = 29), 
and WT (n = 20). Columns and error bars indicate means ± SEM, 
* indicates P < 0.01 between G551D and G1349D.288 Effects of Signature Sequence Mutations on CFTR Gating
Fig. 2 A shows that the relative amount of fully glycosy-
lated proteins (band C) is not different between these 
two mutants and WT-CFTR, confi  rming that these mu-
tant proteins can fold and traffi  c normally to the plasma 
membrane in CHO cells.
It is known that the cAMP-activated currents for 
these two CFTR mutants are extremely small (Drumm 
et al., 1991; Anderson and Welsh, 1992). If we assume 
that plasma membrane expression of WT-CFTR and 
these two mutants is about the same, we can then use 
the whole-cell cAMP-dependent current as a marker 
to quantitatively estimate the gating defects caused by 
these two mutations. We transfected CHO cells with 
WT-CFTR, G551D-CFTR, and G1349-CFTR, in paral-
lel, using the same amount of DNA. Whole-cell patch-
clamp experiments were also performed in parallel to 
minimize variations. Once the whole-cell confi  guration 
was obtained, chloride currents were elicited with 10 μM 
forskolin. The mean current density was calculated as 
the ratio between the net mean current at +100 mV and 
the membrane capacitance. Fig. 2 B shows that the cur-
rent densities of G551D (n = 30) and G1349D (n = 29) 
mutants are lower than that of WT-CFTR (n  = 20). 
However, the current density of G1349D-CFTR is sig-
nifi  cantly larger than that of G551D-CFTR (P < 0.01), 
suggesting that the Po of G1349D-CFTR is higher than 
that of G551D-CFTR.
ATP-dependent Gating of G551D-CFTR and G1349D-CFTR
To investigate the mechanism responsible for the differ-
ent gating behavior of G551D and G1349D mutants, we 
studied both mutants in excised inside-out membrane 
patches. First we examined the ATP-dependent gat-
ing properties of these mutants. After the membrane 
patch was excised into the inside-out confi  guration, 
channels were activated by 1 mM ATP + 25 U/ml PKA. 
Figure 3.  Gating of G551D-CFTR and G1349D-CFTR in excised inside-out membrane patches. (A) A recording of G551D-CFTR 
channel currents in an excised inside-out membrane patch. Note that after washout of ATP and PKA, the channels remained active 
for over 20 min. Expanded current traces show the G551D-CFTR channel activity in the presence of ATP + PKA and during washout. 
(B) Repeated addition and removal of ATP in the same patch did not result in signifi  cant changes of the channel activity of G551D-CFTR. 
(C) A recording of G1349D-CFTR channel currents in an excised inside-out membrane patch. The channels were activated with 1 mM ATP + 
25 U/ml PKA. Upon removal of ATP and PKA, the current decays very rapidly. A small amount of current remains minutes after washout 
of ATP. (D) A recording of WT-CFTR channel currents in an excised inside-out membrane patch. (E) Comparisons of mean macro-
scopic current amplitude for G551D- (n = 16), G1349D- (n = 18), and WT-CFTR (n = 13). Data are presented as means ± SEM.  Bompadre et al. 289
In the case of G551D-CFTR, the elicited currents were 
usually small compared with the macroscopic current 
seen with WT-CFTR (Fig. 3, compare A and D). Surpris-
ingly, when ATP and PKA were removed, the G551D-
CFTR current remained unchanged for tens of minutes 
(n = 46). Fig. 3 A shows a 25-min continuous recording 
of G551D-CFTR. We are confi  dent that the observed 
current arises from G551D-CFTR channels because no 
activity was observed in nontransfected cells and the ob-
served currents were PKA dependent. The single-channel 
amplitude of G551D-CFTR is similar to that of WT 
  channels (see below), and furthermore, glibenclamide, 
a CFTR blocker (Zhou et al., 2002), blocks G551D-
CFTR currents to the same extent as it does to WT-CFTR 
(unpublished data). Repeated addition and removal 
of ATP in the same patch did not result in signifi  cant 
changes of the channel activity (Fig. 3 B), suggesting 
that G551D-CFTR channel activity is ATP independent. 
A similar observation was reported recently by Wang 
et al. (2007). When the same experiment was performed 
with G1349D-CFTR, we observed generally larger cur-
rents than that of G551D-CFTR (e.g., Fig. 3 C). In 
  addition, unlike G551D-CFTR, G1349D-CFTR channel 
current decreases immediately upon ATP washout, a 
property shared with the WT channels (Fig. 3 D). Note 
that for both WT- and G1349D-CFTR a small but signifi  -
cant fraction of the current remained for minutes after 
nucleotide removal.
Fig. 3 E summarizes our results obtained from these 
experiments. The steady-state mean current amplitude 
(a product of the number of functional channels, Po 
and single-channel amplitude) shows a similar pattern 
as that of whole-cell recordings (i.e., WT > G1349D > 
G551D). It should be noted that it is very diffi  cult to cal-
culate accurately the Po and closed time of the channel 
using traditional methods due to the low open proba-
bilities of these mutants (thus the number of functional 
channels cannot be ascertained). Since the single- channel 
amplitude is not altered by the mutations (see Fig. 
4 D), we can compare the Po if we assume that the num-
ber of functional channels is roughly the same. We es-
timated the Po of the mutants by scaling the value of 
the WT Po using the mean current amplitudes shown in 
Fig. 3 E. This method, although not entirely precise, will 
give us some rough estimation of the Po values for the 
mutants. Since the Po for WT channels in the presence 
of 1 mM ATP is 0.45 ± 0.04 (see Fig. 9 D), the esti-
mated Po are ≅ 0.0037 for G551D (120 times smaller 
than the WT Po), and ≅ 0.045 (10 times smaller than the 
WT Po) for G1349D. We then analyzed single-channel 
traces to obtain the mean open time for the mutants 
Figure 4.  Comparison of the mean open times of G551D-, 
G1349D-, and WT-CFTR. (A) Expanded single-channel current 
traces in the presence of 1 mM ATP for G551D-, G1349D-, and 
WT-CFTR. (B) Comparisons of the mean open times and single 
channel amplitudes (n = 6–14 for each data point). Data are 
  presented as means ± SEM.
Figure 5.  Effect of [Mg2+] in the closing rate of WT and G551D-
CFTR. Currents were activated by 1 mM ATP + PKA in a Mg2+-
containing solution. (A) Withdrawal of ATP + PKA and Mg2+ 
ions results in channels closing more slowly for WT-CFTR. Note 
that some channels remain open for tens of seconds. (B) G551D-
CFTR channel openings remain unaltered when ATP, PKA, and 
Mg2+ are removed from the perfusion solution (n = 6). 290 Effects of Signature Sequence Mutations on CFTR Gating
(see Materials and methods for details). Fig. 4 shows ex-
panded single-channel traces for the two mutants and WT-
CFTR. At 1 mM ATP, the mean open time was 367 ± 42 ms 
(n = 14) and 422 ± 33 ms (n = 5) for G551D- and G1349D-
CFTR, respectively. Thus, the mutations do not seem to 
signifi  cantly alter the open time of the channels since 
the mean open time for WT-CFTR channels is 379 ± 
54 ms (n = 7, from Zhou et al., 2006) at this ATP con-
centration. It is interesting to note that Cai et al. (2006) 
found that the G551D and G1349D mutations shorten 
the open time of the channels. Differences in experi-
mental conditions and/or analysis methods may account 
for this discrepancy.
Since free [Mg2+] is known to affect the open time of 
WT-CFTR, presumably by altering the ATP hydrolysis 
rate (Dousmanis et al. 2002), we next examined the ef-
fect of Mg2+ on the closing rate of G551D- and G1349D-
CFTR channels. Fig. 5 shows representative traces for 
WT and G551D-CFTR. Indeed, for WT-CFTR the clos-
ing rate decreases upon withdrawal of Mg2+ ions and 
ATP in the perfusion solution. That is not the case for 
G551D-CFTR, where the current remains unaltered 
when we switch from Mg2+-containing solution to Mg2+-
free solution without ATP (n = 6). The mean open time 
for G551D-CFTR in the Mg2+-free solution is 311 ± 85 ms 
(n = 3), similar to the open time observed in the Mg2+-
containing solution. Surprisingly, we also did not observe 
an increase in the open time in G1349D channels, 
  although some ATP dependence is retained for this 
  mutant (n = 6; unpublished data).
Effect of ADP and AMP-PNP on G551D-CFTR 
and G1349D-CFTR Channels
The results shown above indicate that G551D and 
G1349D, mutations at the equivalent position in the 
  signature sequence of NBD1 and NBD2, respectively, 
  exhibit different gating defects. To further characterize 
their defective functions, we examined effects of ADP and 
AMP-PNP on these two mutants. Previous studies have 
established that the presence of ATP increases the open-
ing rate of WT-CFTR, and that ADP competes with ATP 
for the binding site that opens the channel (Anderson 
and Welsh, 1992; Winter et al., 1994; Bompadre et al., 
2005a). Fig. 6 A shows a representative result for WT 
channels. In excised patches, after activation of the 
channels with 1 mM ATP + PKA, 500 μM ADP inhibits 
WT channel currents, elicited with 500 μM ATP, by 
 59 ± 2%. However, ADP had little effect on G551D-
CFTR currents (n = 10, Fig. 6 B), further confi  rming 
that G551D channel currents are ATP independent. In 
contrast, G1349D-CFTR channels, like WT-CFTR, can 
be   inhibited by ADP; interestingly however, the level 
of   inhibition was slightly but signifi   cantly less (P < 
0.001),  40 ± 3% (n = 8, Fig. 6 C).
We then tested the nonhydrolyzable ATP analogue 
AMP-PNP. AMP-PNP, when applied in the presence of 
ATP, can lock open WT-CFTR channels for minutes 
(Gunderson and Kopito, 1994; Hwang et al., 1994; 
Mathews et al., 1998). In excised patches, after activa-
tion with 1 mM ATP + PKA, we applied 2 mM AMP-
PNP + 1 mM ATP to WT (Fig. 7 A), G551D (Fig. 7 B), 
Figure 6.  Effect of ADP on G551D, 
G1349D, and WT-CFTR. Representa-
tive current traces for WT-CFTR (A), 
G551D-CFTR (B), and G1349D-CFTR 
(C). Currents from both WT- and 
G1349D-CFTR are reduced by ADP, 
but ADP fails to inhibit G551D-CFTR 
channel currents. (D) Summary of per-
cent inhibition by 500 μM ADP for 
G551D- (n =10), G1349D- (n = 8), and 
WT-CFTR (n = 8). Data are presented 
as means ± SEM. * indicates P < 0.001 
between G1349D and WT.  Bompadre et al. 291
and G1349D channels (Fig. 7 C). Note that in the case 
of WT channels, the current was macroscopic, and single-
channel closing events were observed only after a 
long washout. AMP-PNP locked open the WT channels. 
The locked open time can be obtained from the relax-
ation time constant upon washout of ATP and AMP-
PNP. The calculated locked open time of WT- CFTR 
channels is  73.5 s (from Zhou et al., 2005), which is 
much longer than the open time of the channels in the 
presence of 1 mM ATP alone (379 ± 54 ms). In con-
trast, AMP-PNP failed to increase either the G551D- or 
G1349D-CFTR currents (Fig. 7, B and C). Upon re-
moval of the nucleotides, most of the G1349D-CFTR 
channel currents decreased rapidly (Fig. 7 C). We did 
not observe slow closures of the channels as seen with 
WT-CFTR.
[ATP] Dependence of G551D- and G1349D-CFTR
Our data suggest that the G551D mutation abolished 
nucleotide-dependent gating. It remains possible that 
this mutation lowers ATP binding affi  nity as other muta-
tions in ABP2 (e.g., Y1219G in Zhou et al., 2006; K1250A 
in Vergani et al., 2003). Since the signature sequence 
  itself is not an ATP binding site before the two NBDs 
  dimerize (Locher et al., 2002; Smith et al., 2002; Lewis 
et al., 2004), it seems unlikely that the G551D mutation 
will affect ATP dose–response relationship, which re-
fl  ects ATP affi  nity of the closed state when the NBDs are 
in monomeric confi  gurations. G551D-CFTR activity was 
examined at different [ATP]. Fig. 8 A shows that the 
channel activity of G551D-CFTR is not altered even in 
the presence of 10 mM ATP. These results were further 
quantifi  ed by measuring the ratio of the mean current 
amplitudes in the presence and absence of ATP. This 
ratio is  1 for all [ATP] tested (Fig. 8 B).
We next examined the ATP dependence of G1349D-
CFTR more thoroughly by measuring the activity of the 
channel at different [ATP]. In excised patches, G1349D-
CFTR channels were exposed to 2.75 mM ATP + PKA, 
and then to various ATP concentrations (from 2 μM to 
10 mM). The experiments were performed by quan-
tifying G1349D-CFTR channel current at a test [ATP] 
that was bracketed with 2.75 mM ATP to ensure the 
absence of a time-dependent rundown (for details see 
Zeltwanger et al., 1999). Fig. 9 (A and B) shows repre-
sentative traces for WT- and G1349D-CFTR. Interest-
ingly, the magnitude of current elicited by 50 μM ATP, 
relative to that with 2.75 mM ATP, is larger for G1349D-
CFTR (Fig. 9 B) than for WT-CFTR (Fig. 9 A), suggest-
ing that G1349D-CFTR channels are “more sensitive” 
to ATP than WT-CFTR. Fig. 9 C shows the normalized 
ATP dose response for G1349D-CFTR with an overlaid 
WT-CFTR data for comparison (from Zhou et al., 2006). 
Interestingly, similar to that of WT- CFTR, the G1349D-
CFTR channel activity is saturated at millimolar [ATP], 
but the ATP dose–response relationship is shifted to the 
left. Although this mutant has a maximal Po  10 times 
lower than WT-CFTR (Fig. 9 D), the open time of the 
channel is not sensitive to changes in [ATP] (441 ± 
30 ms in the presence of 10 μM ATP and 422 ± 33 ms in 
the presence of 1 mM ATP). These open time constants 
are not signifi   cantly different from the mean open 
time of WT channels either. Therefore, the differ-
ence in the dose response between WT- and G1349D-
CFTR (apparent Kd and maximal Po) refl  ects effects of 
the mutation on the opening rate of the channel. More 
interestingly, the dose–response curve of G1349D-
CFTR is not as steep as that of WT-CFTR. At low micro-
molar [ATP], the relative fraction of G1349D current 
is higher than that of WT. Qualitatively speaking, as 
the [ATP] is increased, the activity of the G1349D mu-
tant does not increase as much as that of WT channels, 
as if the increasing activation of G1349D-CFTR upon 
Figure 7.  Effect of AMP-PNP on G551D, G1349D, and WT-CFTR. 
Representative current traces for WT-CFTR (A), G551D-CFTR (B), 
and G1349D-CFTR (C). WT-CFTR channels were locked open by 
2 mM AMP-PNP + 1 mM ATP. Neither G551D- nor G1349D-CFTR 
responds to AMP-PNP (n = 4 each).292 Effects of Signature Sequence Mutations on CFTR Gating
  raising [ATP] is accompanied by an inhibitory effect 
that is also ATP dependent.
Kinetic Modeling for G1349D-CFTR
To explain the unusual ATP dose–response relationship 
of G1349D-CFTR, we resort to CFTR gating schemes 
that incorporate two ATP binding sites. We fi  rst tried 
the expanded version of the CFTR gating model proposed 
originally by Vergani et al. (2003) (Scheme A in Fig. 10 A), 
and calculated the steady-state solution for the open 
probability. In Scheme A, ATP binds either to ABP1 or 
to ABP2 before the doubly occupied closed state can 
  sojourn to the open state. Hydrolysis of the ATP mole-
cule bound at ABP2 results in channel closing. It was 
proposed that ATP binding to ABP2 first does not 
occur frequently for WT-CFTR because of a higher 
  affi  nity of ABP1 for ATP (Kd1 = 10 μM and Kd2 = 40 μM, 
from Vergani et al., 2003). We could simulate our 
WT data using Scheme A. Among the parameters, 
ko(2ATP) = 2.5 s−1 and kc(hydro) = 3 s−1 were obtained from 
the closed and open time constants of our data (Zhou 
et al., 2006). Kd1 (10 μM) was obtained from Vergani 
et al. (2003), although it should be noted that this value 
is somewhat arbitrary. Kd2 (130 μM) was chosen to best 
fi  t our ATP dose–response relationship of WT-CFTR 
(Fig. 10 B).
We then tried to fi   t the G1349D data using this 
scheme. To fi  t the G1349D data we need to be able to 
reproduce the shift of the curve, the fl  attening of the 
slope, as well as an  10-fold reduced maximal Po. Since 
the open time for G1349D-CFTR is not signifi  cantly dif-
ferent from that of WT channels, kc(hydro) remains un-
changed. The only way to obtain a maximal Po 10 times 
lower than that of WT was to reduce the opening rate 
(ko(2ATP)) from 2.5 s−1 to 0.15 s−1. However, the resulting 
curve (Fig. 10 C, green line; also see Table I) deviates 
signifi  cantly from the data.
Since the G1349 residue is located in the ABP1, we 
then tested if manipulating the Kd1 could generate data 
with a leftward shift of the dose–response curve. Decreas-
ing Kd1 by as much as 1,000-fold did not produce a 
Figure 8.  ATP dose–response relationship for G551D-CFTR. 
(A) Representative trace for G551D-CFTR in the presence of 
10 mM ATP. Currents were activated with 1 mM ATP + 25 U/ml 
PKA (not depicted). (B) Normalized ATP dose–response 
  relationship for G551D-CFTR. Currents at different [ATP] were 
normalized to the current level in the absence of ATP (washout) 
(n = 4–6 for each data point).
Figure 9.  ATP dose–response for G1349D-
CFTR. Representative traces of WT- 
(A) and G1349D-CFTR (B) channels in 
response to 50 μM and 2.75 mM ATP. Note 
that the amount of current elicited by 50 
μM ATP, relative to the amount of current 
elicited by 2.75 mM ATP, is larger for 
G1349D (ratio = 0.65) than for WT (ratio = 
0.42) in these particular patches. (C) Nor-
malized ATP dose–response relationship 
for G1349D-CFTR (red circles) and WT-
CFTR (blue squares, from Zhou et al., 
2006). (D) Relationships between [ATP] 
and single-channel Po (blue squares for 
WT, from Zhou et al., 2006, and red open 
circles for G1349D). The G1349D Po was 
calculated under the assumption that the 
maximal Po is 10 times lower than WT Po.  Bompadre et al. 293
  signifi  cant shift of the dose–response curve (brown line). 
On the other hand, increasing Kd1 resulted in a curve 
shifted to the right (unpublished data). The leftward 
shift could be reproduced by reducing Kd2 by  5-fold 
(red line, also see Table I). This fi  vefold increase in the 
affi  nity for ATP at ABP2 seems hard to envision when 
one considers that G1349 is located at ABP1. The main 
problem with these results, however, is that they fail to 
reproduce the fl  attening of the dose–response curve.
We further expanded Scheme A to include the spon-
taneous ATP-independent openings that we have ob-
served in various CFTR constructs (Bompadre et al., 
2005b; also Fig. 3 above). This addition can be seen 
in Fig. 11 A, Scheme B, enclosed in an orange box.
The parameters for the spontaneous openings were 
obtained from Bompadre et al. (2005b) (measured for 
∆R-CFTR), and we assumed that ATP binding to ABP1 
has little effect on the ATP-independent opening (i.e., 
kO(SPT0) = kO(SPT1) = kO(SPT)), an assumption supported 
by Zhou et al. (2006) and the current results with the 
G551D mutation (see Discussion). We also assumed 
that the closing rate of both types of spontaneous 
openings is the same (kc(SPT0) = kc(SPT1) = kc(SPT)) since 
the mean open time of G551D-CFTR is approximately 
the same as the mean open time of WT channels in the 
absence of ATP. We calculated the open probability of 
G1349D-CFTR for this expanded model using the same 
kinetic parameters listed in Table I with two added 
new parameters (kc(SPT) = 2 s−1, kO(SPT) = 0.006 s−1; 
fromt Bompadre et al., 2005b). Adding this ATP-
  independent component could not replicate the over-
all shape of the ATP dose response for G1349D-CFTR 
(unpublished data).
We then tested the possibility that the G1349D muta-
tion may affect the opening rate for the spontaneous 
openings. We increased kO(SPT) up to 10-fold, and did 
not obtain a leftward shift or a less steep curve for the 
dose–response relationship. The main effect of increas-
ing kO(SPT) is an increase of the relative open probability 
at low micromolar [ATP], in excess of the measured 
values. On the other hand, when kc(SPT) and kO(SPT) were 
kept the same as those of WT channels, the ratio of the 
G1349D-CFTR current produced by the ATP-independent 
openings to the maximal current (0.057 ± 0.010) is very 
close to what the model predicts (0.06). We should 
point out that even though we could not simulate 
the fl   attening of the dose–response relationship for 
G1349D-CFTR by modifying the opening rate for the 
spontaneous openings, Kd2, and the ATP-dependent 
opening rate (kO(2ATP)), we cannot completely rule out 
the possibility that some combinations of these parame-
ters could produce a curve similar to our data.
Since our previous results implicate a critical role of 
ATP binding at ABP2, but not at ABP1, in channel 
  opening (Powe et al., 2002; Zhou et al., 2006), we further 
expanded Scheme A to include the possibility that the 
Figure 10.  (A) Scheme A: a CFTR gating model expanded from 
one proposed by Vergani et al. (2003). C, ATP·C, and ATP·C·ATP 
are closed states with no ATP bound, one ATP molecule bound to 
ABP1, and two ATP molecules bound, respectively. O2ATP is the 
open state with two bound ATP molecules. Kd1 and Kd2 are the 
dissociation constants of ATP for ABP1 and ABP2, respectively. 
kO(2ATP) is the opening rate and kC(ATP) is the closing rate of the 
channel via hydrolysis. The gray arrow, representing the non-
hydrolytic closing step, has been ignored in our calculation because 
it is exceedingly small compared with the closing rate of the hy-
drolytic closing (same applies to Figure 11). According to this 
model, the channel can open only after the two binding sites are 
occupied by ATP. (B) ATP dose response for WT-CFTR channels 
(red squares) and the simulated curve (blue line) obtained with 
Scheme A and the parameters summarized in Table I. (C) Nor-
malized ATP dose response for G1349D-CFTR channels (red 
  circles) and different simulated results obtained with Scheme A. 
The green line represents a fi  t with the same parameters as WT 
except for a reduced opening rate. Modifi  cation of Kd1 up to 
1,000-fold (brown line) did not reproduce the leftward shift. The 
red line represents simulated data when the ATP affi  nity at ABP2 
is increased by fi  vefold (parameters in Table I).
TABLE I
A Summary of the Kinetic Parameters used in Fig. 10 for Scheme A
Scheme A WT A B C
Kd1 (μM) 10 10 0.01 10
Kd2 (μM) 130 130 130 25
kO(2ATP) (s−1) 2.5 0.15 0.15 0.15
kC(hydro) (s−1)3 3 3 3
For WT-CFTR these parameters result in a good fi  t to the experimental 
data (Fig. 10 B). The parameter sets A, B, and C correspond to different 
attempts to fi  t the G1349D-CFTR data (green, brown, and red lines in 
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channel may open with just one ATP molecule bound 
at ABP2 (i.e., ABP1 is vacant). This new addition is 
  depicted with a green box in Fig. 11, Scheme B. This 
  kinetic scheme (Fig. 11, Scheme B) can successfully 
replicate the WT Po using similar parameters described 
above, with kO(1ATP) = kO(2ATP) = 2.5 s−1 (Fig. 11 B, also 
see summary in Table II). Using Scheme B, we can also 
obtain a dose–response relationship that reproduces all 
the features of the G1349D dose response in at least two 
different ways (Table II). First, without changing any of 
the WT binding parameters for ABP1 or ABP2, simply 
reducing kO (1ATP) to 1 s−1 and kO (2ATP) to 0.16 s−1 can 
produce data strikingly similar to those of G1349D-
CFTR (green line in Fig. 11 C). The dose–response 
curve of G1349D-CFTR can also be successfully re-
produced by slightly decreasing the affi  nity for ATP at 
ABP2 (e.g., by increasing Kd2 to 280 μM) and simulta-
neously lowering the opening rate kO (2ATP) to 0.16 s−1 
(red line in Fig. 11 C). These results thus suggest that 
the G1349D mutation decreases the channel opening 
rate when ABP1 is occupied by ATP (i.e., kO(2ATP)). 
  Possible structural interpretations of this proposition 
will be discussed below.
DISCUSSION
The data presented in the current studies strongly sug-
gest that the G551D mutation of NBD1 completely elim-
inates ATP-dependent gating. The residual low activity 
of G551D-CFTR represents ATP-independent gating 
events. On the other hand, G1349D-CFTR exhibits a 
fairly different behavior than G551D-CFTR; it maintains 
some ATP dependence, but with a lower Po than WT 
channels due to a lower opening rate. Since G551 and 
G1349 are located in ABP2 and ABP1, respectively, these 
results thus support the idea that these two ATP binding 
sites play different roles in ATP-dependent opening of 
the channel. We will discuss the fundamental mecha-
nism responsible for the different behavior of these two 
mutant channels, and the potential clinical implications 
of our results.
The CFTR protein is composed of fi  ve domains: two 
membrane-spanning domains that form the chloride 
channel pore; two nucleotide-binding domains (NBD1 
and NBD2), defi  ned by the conserved Walker A and B 
motifs and a signature sequence, that play critical roles 
in CFTR gating; and a regulatory domain (R domain), 
phosphorylation of which is essential for channel function. 
How ATP binding/hydrolysis controls CFTR   gating 
remains controversial despite more than a decade 
of studies (Gadsby et al., 2006; Zhou and Hwang, 2007). 
Figure 11.  (A) Scheme B: an expanded CFTR gating model pro-
posed in Zhou and Hwang (2007). C, ATP·C, C·ATP, and 
ATP·C·ATP are closed states with no ATP bound, one ATP bound 
to ABP1, one ATP bound to ABP2, and both ABP1 and ABP2 
  occupied, respectively. O1ATP and O2ATP represent open states with 
only ABP2 occupied by ATP or both ABP1 and ABP2 occupied by 
ATP, respectively. OSPT0 and OSPT1 are open states in the ATP-
  independent component with no ATP or one ATP bound to ABP1, 
respectively. Kd1 and Kd2 are the dissociation constants of ATP for 
ABP1 and ABP2, respectively. kO (1ATP) is the opening rate with 
ATP bound at ABP2 (from C·ATP to OATP1); kO (2ATP) is the open-
ing rate with ATP binding to ABP1 and ABP2 (from ATP·C·ATP 
to OATP2). kC(ATP) is the transition rate from open to closed state in 
the hydrolytic pathway both without and with ATP binding to ABP1 
(from OATP1 to C and from OATP2 to C). kO(SPT) and kC(SPT) are the 
opening and closing rates for spontaneous ATP-independent 
gating. (B) Dose–response relationships for WT (red squares) 
and G1349-CFTR (red circles) and calculated data based on 
Scheme B and the parameters summarized in Table II
TABLE II
A Summary of the Kinetic Parameters used in Fig. 11 for Scheme B
Scheme A WT G1349D (a) G1349D (b)
Kd1 (μM) 10 10 10
Kd2 (μM) 130 130 280
kO(1ATP) (s−1) 2.5 1 2.5
kO(2ATP) (s−1) 2.5 0.16 0.16
kC(hydro) (s−1)3 3 3
kO(SPT) (s−1) 0.006 0.006 0.006
kC(SPT) (s−1)2 2 2
These sets of parameters correspond to the fi  ts obtained for WT-CFTR 
(blue line in Fig. 11 B) and G1349D-CFTR (a corresponds to the green 
line in Fig. 11 C; b corresponds to the red line in Fig. 11 C).  Bompadre et al. 295
It is generally agreed that the closure of the channel 
follows hydrolysis of the ATP molecule by the conserved 
motifs in NBD2 (i.e., ABP2). For channel opening, one 
theory predicts that binding of ATP to both ABP1 and 
ABP2 is required for channel opening (Aleksandrov 
et al., 2001; Vergani et al., 2003, 2005; Berger et al., 2005). 
However, Zhou et al. (2006) proposed that binding of 
ATP to ABP2 catalyzes channel opening, while binding 
of ATP at ABP1 may not be required (also see Powe 
et al., 2002; Bompadre et al., 2005b).
The open channel conformation for CFTR likely 
  refl  ects a head-to-tail NBD dimer (Vergani et al., 2005) 
seen in other ABC transporters; opening of the channel 
involves approximation of the two NBDs so that the 
ATP molecules are sandwiched at the dimer interface. 
Thus, the individual ABPs are composed of the Walker A 
and Walker B motifs of one NBD and the signature 
sequence of the partner NBD (Fig. 1). Previous studies 
on the role of ATP binding in CFTR gating have been 
focused mostly on manipulating the Walker A and B 
motifs (e.g., Powe et al., 2002; Vergani et al., 2003). The 
current studies on the mutations in the signature 
  sequence provide novel mechanistic insights into how 
these two ATP binding sites control CFTR gating.
We showed that G551D channels, though still need 
to be phosphorylated to be functional, do not respond 
to ATP at all. This lack of response to ATP also explains 
why the G551D mutant is insensitive to ADP since 
the main effect of ADP is to competitively inhibit 
channel opening by ATP (Bompadre et al., 2005a). As 
  mentioned previously, WT-CFTR channels have a fi  nite 
opening rate in the absence of ATP (Bompadre et al., 
2005b; also see Fig. 3 above). If we propose that all 
the activity observed with the G551D channels repre-
sents spontaneous ATP-independent openings, the Po 
of G551D should be compatible with that of the ATP-
independent activity of WT channels. A quick calcu-
lation gives a Po of  0.003 for the ATP-independent 
activity of WT-CFTR (Po = τo/(τo + τc), where τo is the 
open time of the channel and τc is the closed time of 
the channel from Bompadre et al. (2005b). This value 
is  150-fold less than the maximal Po of WT channels. 
Indeed, in patches containing hundreds of WT chan-
nels (e.g., Fig. 3 D), minutes after ATP is removed,  1% 
of the macroscopic current still remains. Although it is 
very diffi  cult, if not impossible, to estimate precisely 
the Po for G551D from single-channel kinetic analysis, 
we made a rough estimation by comparing macro-
scopic current amplitudes between WT and G551D 
channels if we assume the number of channels in the 
membrane patches is about the same. Fig. 3 E shows 
that the average mean current of G551D-CFTR in ex-
cised patches is  120 times smaller than that of WT 
channels. This result is consistent quantitatively with 
our hypothesis that G551D-CFTR only exhibits ATP-
  independent openings.
What is the underlying molecular mechanism re-
sponsible for G551D’s dysfunction? It should be noted 
that G551 is located in the signature sequence of NBD1, 
which, together with the Walker A and B motifs of 
NBD2, forms ABP2, the site proposed to be critical for 
channel opening by ATP (Zhou et al., 2006; c.f.   Vergani 
et al., 2003). The G to D mutation either com  pletely 
abolishes ATP binding at this site, ABP2, or blocks the 
conformational changes following ATP binding. Bio-
chemical studies of MRP1, an ABC transporter protein 
belonging to the same subfamily as CFTR, suggest that 
mutations of this glycine residue in the signature se-
quence of either NBD have little effect on ATP binding 
(Ren et al., 2004). Thus, the G551D mutation more 
likely hampers the conformational changes at ABP2 
that facilitate NBD dimerization (i.e., channel opening 
by ATP). On the other hand, if we assume, here, that 
the G551D mutation does not affect ATP binding at 
ABP1 (since the mutation is located at ABP2), the fail-
ure of ATP to increase the activity of this mutant sup-
ports the notion that ATP binding at ABP1 alone 
indeed does not catalyze channel opening (Zhou et al., 
2006; Scheme B, Fig. 11). Then, G551D-CFTR open-
ings represent spontaneous openings either with no 
ATP bound at the ABPs or with ATP bound at ABP1. 
Ultimately, this result reinforces the idea that ATP 
binding at ABP2 is responsible for the ATP-dependent 
opening of CFTR. Putting together the current studies 
and previous work (Powe et al., 2002; Zhou et al., 
2006), we have established an asymmetrical role of the 
two ABPs in CFTR gating. It is worth to note that Cai 
et al. (2006) reported that 2’-deoxy ATP can potentiate 
G551D-CFTR channel activity. It will be interesting 
to investigate how and where this ATP analogue exerts 
its effects.
In contrast to G551D-CFTR, G1349D-CFTR still main-
tains some ATP dependence, but has a maximal Po 
 10-fold lower than WT-CFTR. It is interesting to note 
that the inhibition of G1349D-CFTR channels by ADP is 
slightly smaller than the inhibition of WT channels. To 
explain this observation we have to realize that G1349D 
channels also have ATP-independent openings, and 
because of a much lower Po at maximal [ATP], the 
fraction of the total current that originates from the ATP-
independent openings is relatively higher in G1349D 
than in WT channels. Since the ATP-independent 
  activity is insensitive to ADP, the portion of the   total 
current that can be inhibited by ADP is relatively smaller 
in G1349D than WT channels.
If binding of ATP to ABP1 is not essential for channel 
opening as described above, why does the G1349D mu-
tation, located at ABP1, decrease the maximal Po? Since 
the open time of the mutant channel does not differ 
signifi  cantly from that of WT channels, we can conclude 
that the defect of G1349D-CFTR resides in a lowered 
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to decrease ATP binding affi  nity because, fi  rst, the cur-
rent saturates at millimolar [ATP], and, second, the 
ATP dose–response relationship is shifted to the left by 
the mutation (Fig. 9 C). The most intriguing feature of 
G1349D-CFTR is the fl   attened ATP dose–response 
curve, suggesting a negative cooperativity between the 
two ATP binding sites. Based on the results of our mod-
eling, we propose that this negative cooperativity seen 
with the G1349D mutation arises from a negative effect 
on channel opening by ATP binding at ABP1.
Although our calculations provide, at a minimum, 
two different solutions, we prefer the one in which both 
opening rates are diminished (kO (1ATP) = 1 s−1 and 
kO (2ATP) = 0.16 s−1) because this kinetic explanation 
corroborates with recent structural interpretations of 
CFTR gating (Vergani et al., 2005; Zhou et al., 2006). 
The opening of CFTR is coupled to the dimerization of 
CFTR’s two NBDs (Vergani et al., 2005). Zhou et al. 
(2006) further proposed that the opening of the chan-
nel (i.e., dimerization of CFTR’s two NBDs) is initiated 
by ATP binding to ABP2 irrespectively of whether ABP1 
is occupied or not, but the fi  nal approximation of the 
two parts that form ABP1 precedes channel opening. 
Compared with glycine, aspartate has a negatively 
charged side chain. This side chain by itself may steri-
cally hinder NBD dimerization even when ABP1 is not 
occupied by ATP (i.e., a reduced kO(1ATP)). Since the 
D1349 residue should also be physically close to the 
bound ATP when the two NBDs are approaching each 
other upon dimerization (Lu et al., 2005), it is possible 
that the electrostatic repulsion between the negatively 
charged ATP and the negative charge of the aspartate at 
position 1349 hinders the dimerization process even 
more (i.e., an even smaller kO(2ATP)). Future studies us-
ing different mutations at this position and/or nearby 
amino acids should provide further insight into the mo-
lecular mechanism of the gating defects manifested in 
this CF-associated mutant.
It is interesting to note that AMP-PNP does not lock 
open either G551D or G1349D channels. It is known 
that AMP-PNP locks open WT channels after they are 
fi   rst opened by ATP (Gunderson and Kopito, 1994; 
Hwang et al., 1994). Thus AMP-PNP likely binds to a 
state following the ATP-induced open channel confor-
mation. In the case of G551D, it is not surprising that 
we do not see any effects with AMP-PNP because this 
mutation completely eliminates ATP-dependent gating. 
It is however puzzling that AMP-PNP is ineffective on 
G1349D-CFTR. Interestingly, Cai et al. (2006) reported 
that pyrophosphate, an agent that potentiates CFTR by 
a similar mechanism as AMP-PNP, also fails to act on 
G1349D-CFTR. Perhaps, the aspartate side chain of 
G1349D-CFTR prevents the formation of a stable locked-
open conformation. A similar mechanism may also 
account for the lack of effect on the open time of 
G1349D-CFTR by removing free Mg2+.
In addition to the mechanistic insights into how 
CFTR’s two NBDs work concertedly to gate the channel, 
our observations also provide a quantitative explana-
tion for the different phenotypes exhibited in CF pa-
tients carrying the G551D or G1349D mutation. Since 
these two mutations affect neither membrane traffi  ck-
ing nor the single-channel amplitude, the reduction of 
the maximal current by these mutations results solely 
from a decrease in Po. Although it is unknown exactly 
how much functional defect of CFTR is needed to cause 
CF, our data suggest that a 10-fold decrease of maximal 
CFTR channel activity results in mild form CF (compare 
Sheppard et al., 1993). On the other hand, a 100-fold 
decrease of maximal CFTR channel activity is suffi  cient 
to cause severe form CF (compare Wang et al., 2000). 
This quantitative relationship between CFTR activity 
and clinical phenotypes is similar to that proposed pre-
viously by Davis (2001). Future studies of other disease-
associated mutations can lead to a more quantitative 
understanding of the pathophysiology of CF, which 
will then serve to guide therapeutic development for 
patients with CF.
Many CFTR potentiators have been shown to increase 
the currents of one or both of these mutants, sometimes 
with different potencies (Becq et al., 1994; Becq et al., 
1996; Illek et al., 1999; Ai et al., 2004; Moran et al., 2005; 
Pedemonte et al., 2005; Cai et al., 2006). The mecha-
nism by which these CFTR activators work remains 
  unclear (Hwang and Sheppard, 1999; Hwang et al., 2003). 
Since genistein increases the activity of G551D-CFTR 
(e.g., Illek et al., 1999) our results suggest that  genistein’s 
action may involve more than a simple effect on ATP-
dependent gating as previously proposed (  Weinreich, 
et al., 1997; Wang et al., 1998). Nevertheless, it is 
i  nteresting to note that 20 μM genistein increases 
G1349D-CFTR current density 6.8 ± 1.9-fold (n = 14) 
compared with forskolin alone. With this increase, 
G1349D current density is  60% of that of WT, a level 
likely suffi  cient to completely restore the physiological 
function of chloride secretion. On the other hand, 
20 μM genistein increases G551D current density by 
6.5 ± 2.4-fold (n = 19). This may be adequate to reach 
a level of activity similar to that of G1349D-CFTR but 
unlikely to completely restore the physiological func-
tion of this mutant channel. Thus, we believe that the 
current results provide considerable mechanistic infor-
mation for future pharmacological studies, which in 
turn could pave the way for a tailored drug design for 
therapeutical interventions in CF.
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